Welcome to our dedicated page for Rani Therapeutics Holdings SEC filings (Ticker: RANI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Rani Therapeutics Holdings, Inc. (RANI) SEC filings page on Stock Titan provides access to the company’s U.S. Securities and Exchange Commission disclosures, including Current Reports on Form 8-K and other key documents. These filings offer detailed information on material events affecting the clinical-stage biotherapeutics company, which focuses on oral delivery of biologics and drugs through its RaniPill® platform.
Rani’s recent Form 8-K filings have covered financial results and corporate updates, such as quarterly earnings releases where the company reports research and development expenses, general and administrative expenses, net loss figures and cash balances. These filings often incorporate press releases as exhibits, giving investors a structured view of the company’s operating performance and cash runway expectations.
Other 8-K filings document material agreements and capital markets transactions, including securities purchase agreements for private placements, registration rights agreements, amendments to loan and security agreements, and details of warrant issuances and debt conversions. Rani has also filed 8-Ks describing its Collaboration and License Agreement with Chugai Pharmaceutical Co., Ltd. and a collaboration with ProGen Co., Ltd., outlining upfront payments, milestone structures, royalty terms and shared development responsibilities for products that combine partner molecules with the RaniPill or RaniPill HC devices.
Filings further address governance and listing matters, such as notices from The Nasdaq Stock Market LLC regarding minimum bid price compliance, director appointments and resignations, and reconstitution of board committees. Through Stock Titan, users can review these filings alongside AI-powered summaries that highlight the main points of lengthy documents, helping to interpret complex sections on financing terms, collaboration structures and listing requirements without reading every line.
For investors researching RANI, this page is a central resource to examine 10-K and 10-Q reports when available, Form 8-K current reports and any future Form 4 insider transaction filings, with real-time updates from EDGAR and AI-generated explanations that clarify technical language and regulatory disclosures.
Rani Therapeutics Holdings, Inc. closed a private placement of 42,633,337 shares of Class A common stock, together with warrants to purchase up to 125,000,004 shares and pre-funded warrants to purchase up to 82,366,667 shares. Following the closing, shares outstanding were 97,541,221.
In connection with the financing, Andrew Farquharson and Maulik Nanavaty resigned from the board effective upon closing. The company appointed Abraham Bassan and Vasudev Bailey, Ph.D. to the board, naming Mr. Bassan chair of Nominating and Corporate Governance and Dr. Bailey chair of Compensation. For so long as Samsara BioCapital and Anomaly Ventures each beneficially own at least 25% of the securities issued to it at closing (including upon exercise of the warrants), each has the right to designate one board member, subject to Nasdaq rules.
Rani Therapeutics (RANI) reported insider share sales on a Form 4. The reporting person executed open‑market sales of Class A common stock on two dates. On 10/20/2025, they sold 1,923,000 shares at a weighted average price of $2.4115. On 10/21/2025, they sold 4,000,000 shares at a weighted average price of $2.7685.
Following these transactions, the reporting person beneficially owned 2,379,194 shares, held indirectly through South Lake One LLC. The filing notes that the weighted average prices reflect multiple trades within ranges of $2.25–$2.61 and $2.50–$3.09, and detailed trade breakdowns are available upon request. The ownership is reported as indirect, and the form was filed by one reporting person.
Rani Therapeutics entered a private placement to raise approximately $60.3 million in gross proceeds. The Company agreed to sell 42,633,337 Class A shares, issue warrants to purchase up to 125,000,004 shares, and issue pre-funded warrants for up to 82,366,667 shares. Institutional investors will pay $0.48 per share; an affiliated investor will pay $0.605 per share. Pre-funded warrants are exercisable immediately at $0.0001 per share; common warrants become exercisable following stockholder approval and have a five-year term.
As part of the financing, Avenue agreed to convert $6.0 million of loans into 12,500,000 shares (or pre-funded warrants) and will receive warrants to purchase up to 12,500,000 shares on the same terms. Rani also signed a collaboration and license agreement with Chugai, adding $10.0 million upfront, up to $18.0 million in technology transfer milestones, up to $57.0 million in development milestones, up to $100.0 million in sales-based milestones, and single-digit royalties.
The Company will file resale registration statements within 15 days of closing and use reasonable best efforts to have them declared effective 45 days after closing, or 90 days if subject to full review.
Armistice Capital, LLC and Steven Boyd disclosed ownership of 4,312,354 shares of Rani Therapeutics Holdings-A, representing 8.79% of the outstanding common stock. The filing states Armistice Capital acts as investment manager to Armistice Capital Master Fund Ltd., the direct holder of the shares, and that Armistice exercises shared voting and dispositive power over these securities while neither Armistice nor Mr. Boyd report sole voting or dispositive power.
The filing clarifies the Master Fund retains the right to receive dividends or sale proceeds, and includes a joint filing statement executed by Steven Boyd on behalf of both reporting persons.
Rani Therapeutics filed a shelf registration on Form S-3 to replace its prior registration and may offer up to $200,000,000 of Class A common stock, preferred stock, debt securities and warrants in one or more offerings. The company’s Class A common stock trades on Nasdaq under RANI (last reported sale $0.53 on August 7, 2025) and the prospectus states a public float of approximately $32.9 million based on 47,094,467 shares at $0.698 per share (July 14, 2025). The filing notes prior sales of $3.0 million under General Instruction I.B.6, making Rani currently eligible to offer up to approximately $7.9 million of Class A stock under that instruction.
Operationally, Rani is a clinical-stage biotherapeutics company developing the oral RaniPill platform. The RaniPill GO (up to 3 mg microtablets) completed three Phase 1 trials. A high-capacity RaniPill HC (up to 200 µL liquid payload) has preclinical data with antibodies and a peptide and is intended to enter clinical testing in the second half of 2025. The prospectus reiterates there are no approved products, no product revenue, and discloses forward-looking risk including concerns about the company’s ability to raise capital and substantial doubt regarding its ability to continue as a going concern.
FAQ
What is the current stock price of Rani Therapeutics Holdings (RANI)?
What is the market cap of Rani Therapeutics Holdings (RANI)?
